Maintenance chemo shows promise in slowing mesothelioma
NCT ID NCT07411144
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether continuing chemotherapy with gemcitabine after initial treatment can help patients with diffuse pleural mesothelioma keep their cancer under control longer. 64 patients who responded to first-line chemo were randomly assigned to receive gemcitabine or no further treatment. The goal was to see if gemcitabine could delay cancer progression, though it may not extend overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Gemcitabine
- What this could lead to
- If successful, this could offer a way to delay cancer progression in mesothelioma patients after initial chemotherapy, potentially improving quality of life.
- What could go wrong
- This is a small phase 2 trial with only 64 participants, so results may not be definitive. Side effects are common, and the drug may not extend overall survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE PLEURAL MESOTHELIOMA (DPM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Institute, Cairo University
Cairo, Egypt, 11765, Egypt